Search jobs 04-May-2021 Guidewires Market Size and Share: Covid-19 Impact Analysis by Sales Revenue, Future Demands, Growth Factors and Drivers, Emerging Trends, Competitive Landscape and Forecast to 2030 | FMI Report
As per FMI, the global guidewires market is slated to value US$ 3.3 Bn in 2020 and expected to witness a substantial CAGR of over 6.0% between 2020 and 2030.The global guidewires market is slated to reach ~US 6.0 Bn by 2030 according to a new study by consulting firm Future Market Insights. As end-user demand for treating various diseases accelerates, guidewires production has picked up pace in recent years. Advancements in guidewire tip technologies has increased adoption of interventional radiology techniques in image-guided diagnosis and treatment of diseases. Interventional radiology has significantly improved patient recovery outcomes. This is because the procedure involves minimum risk, less pain and faster re
Vascular Closure Devices Market to Witness a Pronounce Growth During 2018-2026 report includes market status and forecast of global and major regions, with introduction of vendors, regions, product types and end industries; and this report counts product types and end industries in global and major regions.
BriefingWire.com, 5/03/2021 - Market Scenario
Global Vascular Closure Devices Market was valued US$ 705 Mn in 2017 and is expected to reach US$ 1286.5 Mn by 2026, at a CAGR of 7.81 % during a forecast period.
The vascular closure devices market is segmented into product, end user, access, hole size, and region.
Global Vascular Closure Devices Market
On the basis of the end user, the interventional cardiology segment is expected to dominate the market due to the high prevalence of cardiovascular diseases and the rapidly increasing heavy population.
Intellia Therapeutics, Inc. (NASDAQ: NTLA) (before the market open)
Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) (before the market open)
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) (before the market open)
Insmed Incorporated (NASDAQ: INSM) (before the market open)
Fulcrum Therapeutics, Inc. (NASDAQ: FULC) (before the market open)
Endo International plc (NASDAQ: ENDP) (before the market open)
Bio-Techne Corporation (NASDAQ: TECH) (before the market open)
Harvard Bioscience, Inc. (NASDAQ: HBIO) (before the market open)
Athenex, Inc. (NASDAQ: ATNX) (before the market open)
Zoetis Inc. (NYSE: ZTS) (before the market open)
Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (before the market open)
Syros Pharmaceuticals, Inc. (NASDAQ: SYRS) (before the market open)
Mechanical circulatory support protocol beneficial in acute MI, cardiogenic shock Source:
Basir MB, et al. Featured Clinical Research: Acute coronary and cardiogenic shock. Presented at: Society for Cardiovascular Angiography and Interventions Scientific Sessions; April 28-May 1, 2021 (virtual meeting). Disclosures: The study was funded in part by Abiomed and Chiesi. Basir reports he consults for Abbott Vascular, Abiomed, Cardiovascular Systems Inc., Chiesi, Procyrion and Zoll. ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Subscribe ADDED TO EMAIL ALERTS
You ve successfully added to your alerts. You will receive an email when new content is published.
Claim construction is the heart of validity and infringement for almost every patent proceeding. Yet, at least two recent cert petitions brought from separate cases by Intel and Akeva.